Evidence map›Paper›PMID 33392826›Full record

ArticleJournal of neural transmission (Vienna, Austria : 1996)2021

Effect of the mGlu

Imane Frouni, Cynthia Kwan, Stephen G Nuara, Sébastien Belliveau, Woojin Kang, Adjia Hamadjida, Dominique Bédard, Jim C Gourdon, Philippe Huot

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neural transmission (Vienna, Austria : 1996), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. The anti-dyskinetic effect of the clinic-ready mGluRNaunyn-Schmiedeberg's archives of pharmacology · 2025
    Article
  2. Positive allosteric mGluRNaunyn-Schmiedeberg's archives of pharmacology · 2024
    Article
  3. Effect of mGluRNaunyn-Schmiedeberg's archives of pharmacology · 2024
    Article
  4. Article
  5. The mGluRNaunyn-Schmiedeberg's archives of pharmacology · 2023
    Article
  6. Distribution of [Naunyn-Schmiedeberg's archives of pharmacology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Imane FrouniNeurodegenerative Disease Group, Montreal Neurological Institute, Montreal, QC, Canada.ORCID http://orcid.org/0000-0001-6779-8713
Cynthia KwanNeurodegenerative Disease Group, Montreal Neurological Institute, Montreal, QC, Canada.ORCID http://orcid.org/0000-0002-3878-6745
Stephen G NuaraComparative Medicine & Animal Resource Centre, McGill University, Montreal, QC, Canada.
Sébastien BelliveauNeurodegenerative Disease Group, Montreal Neurological Institute, Montreal, QC, Canada.ORCID http://orcid.org/0000-0002-6652-0899
Woojin KangNeurodegenerative Disease Group, Montreal Neurological Institute, Montreal, QC, Canada.
Adjia HamadjidaNeurodegenerative Disease Group, Montreal Neurological Institute, Montreal, QC, Canada.
Dominique BédardNeurodegenerative Disease Group, Montreal Neurological Institute, Montreal, QC, Canada.
Jim C GourdonComparative Medicine & Animal Resource Centre, McGill University, Montreal, QC, Canada.
Philippe HuotNeurodegenerative Disease Group, Montreal Neurological Institute, Montreal, QC, Canada. philippe.huot@mcgill.ca.ORCID http://orcid.org/0000-0002-5464-8334
Montreal Neurological Institute and Hospital · CAMcGill University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advanced Parkinson's disease (PD) is often complicated by the occurrence of dyskinesia, motor fluctuations and psychosis. To this day, few treatment options are available for each of these phenomena, and they are at times not effective or elicit adverse events, leaving some patients short of therapeutic options. We have recently shown that positive allosteric modulation of metabotropic 2 (mGlu

Indexed as

Dyskinesia, Drug-InducedParkinsonian DisordersPsychotic Disorders1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAnimalsAntiparkinson AgentsBehavior, AnimalCallithrixHumansLevodopa1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAntiparkinson AgentsLevodopaCBiPESDyskinesiamGlu2 receptorMPTP-lesioned marmosetParkinson’s diseasePsychosis

Identifiers

PMID33392826
OpenAlexW3119610899

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.